Abstract. Vascular smooth muscle cell (VSMC) proliferation is a primary pathological event in atherosclerosis (AS), and homocysteine (Hcy) is an independent risk factor for AS. However, the underlying mechanisms are still lagging. Studies have used the combination of methylation of promoters of multiple genes to diagnose tumors, thus the aim of the current study was to investigate the role of methylation status of several genes in VSMCs treated with Hcy. CpG islands were identified in the promoters of platelet-derived growth factor (PDGF), p53, phosphatase and tensin homologue on chromosome 10 (PTEN) and mitofusin 2 (MFN2). Hypomethylation was observed to occur in the promoter region of PDGF, hypermethylation in p53, PTEN and MFN2, and hypomethylation in two global methylation indicators, aluminium (Alu) and long interspersed nucleotide element-1 (Line-1). This was accompanied by an increase in the expression of PDGF, and reductions of p53, PTEN and MFN2, both in mRNA and protein levels. An elevation of S-adenosylmethionine (SAM) and a reduction of S-adenosylhomocysteine (SAH) and the SAM/SAH ratio were also identified. In conclusion, Hcy impacted methylation the of AS-associated genes and global methylation status that mediate the cell proliferation, which may be a character of VSMCs treated with Hcy. The data provided evidence for mechanisms of VSMCs proliferation in AS induced by Hcy and may provide a new perspective for AS induced by Hcy.
Introduction
Previous studies have demonstrated that elevated levels of homocysteine (Hcy) have been implicated as an independent risk factor for atherosclerosis (AS) (1) (2) (3) . Studies have focused on the involvement of Hcy on the dysfunction and injury of vascular cells, such as vascular smooth muscle cells (VSMCs) (4, 5) . It has been previously observed that Hcy induced VSMCs proliferation, however the underlying mechanisms remain to be fully elucidated (6) .
Hcy is a non-protein, sulfur containing amino acid, which is a metabolic intermediate of the methionine cycle. It is a precursor of S-adenosylmethionine (SAM), the unique methyl group donor for DNA methylation (7) . Subsequent to transfer of the methyl group, SAM is transformed into S-adenosylhomocysteine (SAH), which can be hydrolyzed to form Hcy (8) . DNA methylation refers to the addition of a methyl group to the 5 position of cytosine in the context of a CpG dinucleotide. Increasing evidence indicates that human diseases, including AS, are either caused or impacted by abnormal methylation (9) . A previous study suggested that Hcy may also be involved in disturbing the expression of AS-associated genes through the interference of DNA epigenetic phenotype modification, such as DNA methylation (10) . An additional previous study demonstrated that abnormal DNA methylation of genes including peroxisome proliferator-activated receptor α, apolipoprotein E (ApoE) and genomic DNA contribute to the development of AS induced by Hcy (11, 12) . Studies have identified DNA methylation profiling of the vascular tissues in the setting of AS or atherosclerotic plaques (13, 14) . However, the methylation status of several key genes that characterized the VSMC proliferation induced by Hcy in single VSMCs remains to be elucidated. In addition, it remains unclear whether Hcy affected the methylation status and caused proliferation.
In the present study, platelet-derived growth factor (PDGF), p53, phosphatase and tensin homologue on chromosome 10 (PTEN) and mitofusin 2 (MFN2), which are associated with cell proliferation regulation, and two global methylation indicators, aluminium (Alu) and long interspersed nucleotide element-1 (Line- 
Materials and methods
Cell culture. Primary culture of VSMCs was obtained from the media of the umbilical vein of human as previously described (15 
Nested methylation-specific-polymerase chain reaction (nMS-PCR) for methylation analysis.
The detection of methylation levels was conducted as previously described (16) . The summary of primers and product sizes of the nMS-PCR assays are presented in Table I . The PCR products were separated by electrophoresis through a 2% agarose gel containing ethidium bromide. DNA bands were visualized by Gel Documentation and Analysis System ChemiDoc XRS (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and calculated by the formula: Methylation % = methylation/(methylation + unmethylated) x 100%. ) for 90 min, allowing the pre-stained marker to be completely transferred from the gel to the membrane. The gel was then discarded and the membrane was incubated at room temperature in 5% non-fat milk prepared with phosphate-buffered saline with 0.05% v/v Tween-20 (PBS-T) buffer. A total of 2 h later, the membrane was cut as required, placed in a suitable hybridization bag with 1 ml of primary antibody [all primary antibodies were diluted to 1:1,000 with 1% non-fat milk; anti-PDGF (cat. no. ab23914), anti-p53 (cat. no. ab26), anti-PTEN (cat. no. ab32199), anti-MFN2 (cat. no. ab56889) and anti-β-actin (cat. no. ab8227) antibodies were obtained from Abcam, Cambridge, UK] and were incubated at 4˚C. The membrane was washed three times with PBS-T and the mouse anti-goat horseradish peroxidase-conjugated secondary antibody (cat. no. sc-2354; 1:2,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) was added for 2 h at room temperature. Blots were developed on X-ray film (Kodak, Shanghai, China). The protein bands were visualized and analyzed using the Gel Documentation and Analysis System ChemiDoc XRS system with Image Lab software (version 4.1; Bio-Rad Laboratories, Inc.), and calculated by the gray value of the bands.
SAM and SAH concentrations examined by HPLC.
The concentrations of SAM and SAH were determined by high performance liquid chromatography (HPLC). Samples were loaded into a C18 column (Shimadzu, Tokyo, Japan), run by a Hitachi L2000 HPLC system (HPLC; D-2000 Elite HPLC; Hitachi High Technologies, Tokyo, Japan). Absorption of eluted compounds was monitored at (λ) ex=254 nm. Elution of SAM and SAH was achieved at a flow rate of 1.0 ml/min with the mobile phase ammonium format solution. Chromatograms were recorded using a D-2000 Elite integrator. SAM and SAH standards were used to identify the elution peaks, and the SAM and SAH values of the tissues were calculated with the standard curve.
Statistical analysis. Each experiment was repeated 3 times.
Results were expressed as the mean ± standard deviation.
One-way analysis of variance was used to compare the means of multiple groups, followed by Newman-Keuls test. P≤0.05 was considered to indicate a statistically significant difference.
Results
The bioinformatics analysis of promoters in PDGF, p53, PTEN and MFN2. As a key epigenetic modification of the genome, DNA methylation occurs almost exclusively in the context of CpG dinucleotides, particularly in the CpG islands (18) . Ranging from 0.5-5 kb and occurring on average every 100 kb, CpG islands are GC rich (50-70%) and have a ratio of CpG:GpC of at least 0.6 (19) . Collectively, CpG islands account for 1-2% of the genome and their location is primarily in the 5' regulatory regions of all housekeeping genes as well as up to 40% of tissue-specific genes (20) . CpG methylation is associated with gene silencing, and to identify whether CpG islands exist in the chosen genes PDGF, p53, MFN2 and PTEN, the 5'-flanking region of the genes was analyzed using an online search engine (www.urogene.org/cgi-bin/methprimer/methprimer. cgi). The criteria of the CpG island is a CpG-rich region length more than 100 bp, GC percentage >50%, and observe/expect ratio >0.60. As presented in Fig. 1 , at least one CpG island was identified in the DNA promoter regions of all the 4 genes. In the PTEN gene promoter, 6 CpG islands were observed, which indicated that they had greater potential to be modified by DNA methylation and regulated their expression.
PDGF, P53, PTEN, MFN2, Alu and line-1 methylation levels in VSMCs.
To ascertain whether DNA methylation occurred in these genes, the methylation status of genes was analyzed by nMS-PCR. For PDGF, as presented in Fig. 2A , the methylation status of PDGF is increased, particularly, in the 100 µM Hcy group, in which it was increased 7.6-fold, compared with the untreated group (P<0.01). For p53, as presented in Fig. 2B , p53 methylation levels were increased in a dose-dependent manner with the Hcy concentration. For PTEN and MFN2, the methylation levels were elevated by treatment with Hcy ( Fig. 2C and D) , however, it was not dose-dependent. Notably, the most marked effect was observed in the 100 µM group. When treated with folate, the methylation levels of PDGF, PTEN and MFN2 were decreased compared with that of the 100 µM group (P<0.05). It was known that Hcy impacted the gene-specific methylation, however it remained unclear whether it affected the global methylation status, Alu and LINE-1 methylation status is considered as a good indicator of global methylation (21), thus these methylation levels were detected in VSMCs treated by Hcy. The results indicated that both Alu and LINE-1 were in a hypo-methylated state ( Fig. 2E and F; P<0.01) . No significant difference was observed in 100 µM group, however the results in the 50 µM group were significant. In addition, the folate group exhibited an antagonistic effect (P<0.05).
AZC, an inhibitor of DNA methylation, was added, and co-incubated VSMCs were treated with different concentrations of Hcy, then the methylation levels of Alu and Line-1 were measured with nMS-PCR. When compared with untreated cells, the methylation levels of Alu and Line-1 were suppressed in the Hcy treated groups. These data indicated that Hcy impacted the methylation status of these genes and that this may contribute to the proliferation of VSMCs induced by Hcy.
PDGF, P53, PTEN and MFN2 expression levels in Hcy-treated
VSMCs. It was identified that Hcy affected the methylation Figure 1 . The bioinformatics analysis of promoters in PDGF, P53, PTEN and MFN2. The properties of CpG islands in the proximal region of the PDGF promoter were examined using the CpG Island Search engine (www.urogene.org/cgi-bin/methprimer/methprimer.cgi). At least one CpG island exists in the promoter region in all of the four genes. The light blue regions and the blue lines represent the CpG islands. PDGF, platelet-derived growth factor; PTEN, phosphatase and tensin homologue on chromosome 10; MFN2, mitofusin 2. levels of genes, however whether this further impacted the expression remained unclear. In order to investigate whether this occurred in VSMCs treated by Hcy, the mRNA and protein levels of the genes were assayed by RT-qPCR and western blotting. As presented in Fig. 3A , PDGF mRNA and protein expression levels were increased in a dose-dependent manner. p53, PTEN and MFN2 were decreased in the 50, 100, 200 and 500 µM Hcy groups (Fig. 3B-D) . The expression levels of p53, PTEN and MFN2 consistently exhibited the greatest effects in the 100 µM group. In addition, more folate suppressed the changes induced by Hcy. When treated with AZC, the antagonist of DNA methylation, the expression of PDGF, p53, PTEN and MFN2 increased significantly (P<0.05). These data suggested that Hcy affected the # P<0.05, ## P<0.01, vs. the 100 µM Hcy group. PDGF, platelet-derived growth factor; PTEN, phosphatase and tensin homologue on chromosome 10; MFN2, mitofusin 2; Alu, alumninium; Line-1, long interspersed nucleotide element-1; nMS-PCR, nested methylation-specific-polymerase chain reaction; VSMCs, vascular smooth muscle cells; Hcy, homocysteine; AZC, 5-aza-2'-deoxycytidine. expression of the genes, which may be involved in the DNA methylation process.
SAM and SAH levels in VSMCs treated with
Hcy. Similar to Hcy, SAM and SAH are intermediates in the methionine metabolism, and are important factors in the transmethylation process (22) . The SAM and SAH levels were measured using HPLC in the VSMCs, which were treated with Hcy. As presented in Fig. 4 , the results demonstrated that the intracellular levels of SAH were significantly increased, compared with the control group, while the concentrations of SAM and the ratio of SAM/SAH were decreased, when Hcy concentrations increased (P<0.05; Fig. 4 ). SAH levels increased and SAM levels decreased (P<0.05), when VSMCs were treated with Hcy.
Discussion
VSMCs are major components of the arterial wall, and abnormal proliferation of VSMCs serves a pivotal role in the pathogenesis of AS (23) . As an important independent risk factor of AS, Hcy stimulated the VSMCs proliferation, which was identified in previous studies (6, 24) . Cellular proliferation is associated with the regulation of key genes. Thus in the present study, 4 genes were selected for analysis; PDGF, p53, PTEN and MFN2. PDGF is a potent mitogen, which serves crucial roles in developmental and physiological processes, in addition to being directly implicated in proliferative disorders, and it is a potent stimulator of VSMC growth (25) . p53 is a key tumor suppressor and a key regulator of various signaling pathways, including cell-cycle regulation, induction of apoptosis, development and differentiation (26) . In vivo, p53 expression is negatively correlated with markers of cell proliferation in human atherosclerosis; adenoviral expression of p53 reduces cellular proliferation in the rat carotid artery (27) , and by contrast, siRNA of p53 increases cellular proliferation (28) . In p53 -/-/ApoE -/-mice, p53 have been demonstrated to increase aortic plaque formation, with increased rates of cell proliferation and reduced rates of apoptosis in brachiocephalic artery plaques (29) . PTEN is well known tumor suppressor and is additionally involved in regulation of a variety of physiological and pathological processes, including cell proliferation, differentiation, apoptosis, adhesion and migration (30) . PTEN was expressed endogenously in VSMCs, and overexpression of PTEN significantly inhibited basal and PDGF-mediated VSMC proliferation and migration (31) . PTEN overexpression in VSMCs using adenoviral transfection resulted in inhibition of cell proliferation and migration induced by angiotensin II (32) . MFN2 was first cloned from VSMCs in spontaneous hypertensive rats using the differential display technique (33) , which restrained the proliferation of VSMCs mediated by inhibition of extracellular signal-related kinase/mitogen-activated protein kinase signaling and subsequent cell-cycle arrest. The expression changes of these key genes may involve in the imbalance of cell proliferation. The present study indicated an elevation of PDGF, and a reduction of p53, PTEN and MFN2 in VSMCs treated with Hcy, which indicated that Hcy impacted the expression of these genes and resulted in the proliferation of VSMCs.
DNA methylation is an important epigenetic modification at the transcriptional level, which commonly occurs at the CpG dinucleotides of gene promoter regions, particularly in the promoter-associated CpG islands (34) . Consistent with these important roles, a growing number of human diseases have been identified to be associated with aberrant DNA methylation. In the present study, CpG islands were searched for in the promoters of the selected genes, PDGF, p53, PTEN and MFN2, using two CpG island search engines. It was identified that at least one CpG island exists in the promoter regions of all 4 genes. In the promoter region of PTEN, 6 CpG islands were identified, which indicated that they have potential to be modified by DNA methylation and regulate their expression.
It was previously repor te d t hat Hcy cause d cell-type-specific hypomethylation in endothelial cells, VSMCs and foam cells (35) and it was hypothesized that Hcy metabolism and methylation may be associated, resulting in tissue-specific pathology in AS. In addition, DNA methylation also impacts the selected genes PDGF, p53, PTEN and MFN2. In the present study, the key genes associated with cell proliferation regulation were selected in order to investigate the methylation changes in the single VSMCs. In the VSMCs treated with Hcy, hypermethylation or hypomethylation was observed to occur in the promoters of the selected genes, of which PDGF was hypomethylated and p53, PTEN, MFN2 were hypermethylated. Furthermore, the expression levels were altered from normal to aberrant levels. When treated with AZC, an antagonist of DNA methylation, both the methylation status and the expression of the four genes was altered. These results demonstrate that Hcy affected the expression of the genes, which may be involved in the DNA methylation process.
In order to try to confirm the methylation status characteristics in the VSMCs affected by Hcy, we detected global methylation levels were measured. In general, Alu and LINE-1 elements are methylated in somatic tissues, however are hypomethylated in human cancer (36) . In the present study, Hcy was observed to reduce the methylation levels of Alu and LINE-1. In the VSMCs, Hcy not only affected the methylation levels of particular genes, however additionally impacted the global methylation status. Hcy-associated methylation changes are also suggested as a biomarker for use in the prevention and therapy of AS in the future.
In the methionine cycle, SAM is the key methyl donor for cellular methylation events including DNA methylation, and this process produces SAH. SAH is converted to Hcy in a reversible reaction, and elevated levels of SAH and concomitant increases in the SAH/SAM ratio are suggested to inhibit cellular methylation reactions (37) . The present study observed an increase of SAM and a decrease in the SAM/SAH ratio, which demonstrated that Hcy amassment accumulated in the methionine cycle, and caused the SAM, SAH and SAM/SAH ratio changes, then affected methylation process. Furthermore, in the cycle, folate is integrally involved in both substrate synthesis and product removal via its role in methionine synthesis from Hcy. Folate insufficiency leads to a decrease in SAM synthesis (38) , which may compromise SAM-dependent methylation reactions, however additionally also leads to an increase in cellular concentrations of SAH by promoting Hcy accumulation via reversal of SAH hydrolase. In the present study, folate was added to reduce the Hcy effect. The results indicated an antagonistic effect against Hcy both in the methylation levels and in the gene expression levels. These data indicated that Hcy may impact the methylation status partly through the methionine cycle.
In conclusion, Hcy impacted the methylation status of the genes involved in the cell proliferation, leading to a loss of cellular control in VSMCs, and induced the proliferation of VSMCs. Hcy not only affected the methylation levels of special genes, however additionally impacted the global methylation status, which may be a characteristic of VSMCs treated with Hcy. The data provided evidence for the mechanisms of VSMC proliferation in AS induced by Hcy and may provide a potential diagnostic marker for AS induced by Hcy.
